Galectin-3 inhibition by a small-molecule inhibitor reduces both pathological corneal neovascularization and fibrosis

Investigative Ophthalmology and Visual Science

Volumn 58, Issue 1, 2017, Pages 9-20

  Chen, Wei Sheng ^a,d   Cao, Zhiyi ^b   Leffler, Hakon ^c   Nilsson, Ulf J ^c   Panjwani, Noorjahan ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b NEW ENGLAND EYE CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

33DFTG; Angiogenesis; Cornea; Fibrosis; Galectin

Indexed keywords

3,3' DIDEOXY 3,3' BIS [4 (3 FLUOROPHENYL) 1H 1,2,3 TRIAZOL 1 YL] 1,1' SULFANEDIYL DI BETA D GALACTOPYRANOSIDE; AGENTS ACTING ON THE EYE; ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; EYE DROPS; GALECTIN 3; RECOMBINANT PROTEIN; SILVER NITRATE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; CORNEA CELL; CORNEA DISEASE; CORNEA FIBROSIS; CORNEA NEOVASCULARIZATION; CYTOTOXICITY ASSAY; ENDOTHELIUM CELL; EXPERIMENTAL EYE DISEASE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; CORNEA; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; METABOLISM; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; CORNEA; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FIBROSIS; FLOW CYTOMETRY; GALECTIN 3; HUMANS; MALE; MICE; MICE, INBRED C57BL; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85009154370     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-20009     Document Type: Article

References (61)

1. Shakiba Y, Mansouri K, Arshadi D, Rezaei N. Corneal neovascularization: molecular events and therapeutic options. Recent Pat Inflamm Allergy Drug Discov. 2009;3:221-231
2. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249
3. Cogan DG, Kuwabara T. Lipid keratopathy and atheroma. Circulation. 1958;18:519-525
4. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology. 2010;117:1300-1305, e1307
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257
6. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789-791
7. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403
8. Ventrice P, Leporini C, Aloe JF, et al. Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother. 2013;4:S38-S42
9. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415-429
10. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603
11. Tranos P, Vacalis A, Asteriadis S, et al. Resistance to antivascular endothelial growth factor treatment in agerelated macular degeneration. Drug Des Devel Ther. 2013;7: 485-490
12. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol. 2007;91:1318-1322
13. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511
14. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVENUP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292-2299
15. Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915-924, e912
16. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117: 524-529
17. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest. 2007;117:576-586
18. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79:214-221
19. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028-1040
20. Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta. 2002;1572:209-231
21. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29-41
22. Chen WS, Cao Z, Truong L, Sugaya S, Panjwani N. Fingerprinting of galectins in normal, P. aeruginosa-infected, and chemically burned mouse corneas. Invest Ophthalmol Vis Sci. 2015;56:515-525
23. Sugaya S, Chen WS, Cao Z, et al. Comparison of galectin expression signatures in rejected and accepted murine corneal allografts. Cornea. 2015;34:675-681
24. Olbryt M, Jarzab M, Jazowiecka-Rakus J, Simek K, Szala S, Sochanik A. Gene expression profile of B 16(F10) murine melanoma cells exposed to hypoxic conditions in vitro. Gene Expr. 2006;13:191-203
25. Greijer AE, van der Groep P, Kemming D, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol. 2005;206:291-304
26. Hu R, Jin H, Zhou S, Yang P, Li X. Proteomic analysis of hypoxia-induced responses in the syncytialization of human placental cell line BeWo. Placenta. 2007;28:399-407
27. Markowska AI, Jefferies KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem. 2011;286:29913-29921
28. Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGFand bFGF-mediated angiogenic response. J Exp Med. 2010;207:1981-1993
29. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172:288-298
30. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006;103:5060-5065
31. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185:537-546
32. Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33:67-75
33. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180:2650-2658
34. Peng X, Wang J, Lassance-Soares RM, et al. Gender differences affect blood flow recovery in a mouse model of hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2011;300:H2027-H2034
35. De Rossi G, Scotland R, Whiteford J. Critical factors in measuring angiogenesis using the aortic ring model. J Genet Syndr Gene Ther. 2013;4:1000147
36. Guo X, Hutcheon AE, Melotti SA, Zieske JD, Trinkaus-Randall V, Ruberti JW. Morphologic characterization of organized extracellular matrix deposition by ascorbic acid-stimulated human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2007; 48:4050-4060
37. Stegmayr J, Lepur A, Kahl-Knutson B, et al. Low or no inhibitory potency of the canonical galectin carbohydrate binding site by pectins and galactomannans. J Biol Chem. 2016;291:13318-13334
38. Delaine T, Collins P, Mac Kinnon A, et al. Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition. Chembiochem. 2016;17:1759-1770
39. Bargagna-Mohan P, Lei L, Thompson A, et al. Vimentin phosphorylation underlies myofibroblast sensitivity to withaferin A in vitro and during corneal fibrosis. PLoS One. 2015; 10:e0133399
40. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86:322-328
41. Chen WS, Cao Z, Sugaya S, et al. Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3. Nat Commun. 2016;7:11302
42. Saravanan C, Liu FT, Gipson IK, Panjwani N. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J Cell Sci. 2009;122:3684-3693
43. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12:348-360
44. Jester JV, Moller-Pedersen T, Huang J, et al. The cellular basis of corneal transparency: evidence for ‘‘corneal crystallins.’’ J Cell Sci. 1999;112(pt 5):613-622
45. Wilson SE. Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency. Exp Eye Res. 2012; 99:78-88
46. Mohan RR, Hutcheon AE, Choi R, et al. Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK. Exp Eye Res. 2003;76:71-87
47. Kawashima M, Kawakita T, Higa K, et al. Subepithelial corneal fibrosis partially due to epithelial-mesenchymal transition of ocular surface epithelium. Mol Vis. 2010;16:2727-2732
48. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160-171
49. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal. 2009;3:89-94
50. Blalock TD, Duncan MR, Varela JC, et al. Connective tissue growth factor expression and action in human corneal fibroblast cultures and rat corneas after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2003;44:1879-1887
51. Secker GA, Shortt AJ, Sampson E, Schwarz QP, Schultz GS, Daniels JT. TGFbeta stimulated re-epithelialisation is regulated by CTGF and Ras/MEK/ERK signalling. Exp Cell Res. 2008; 314:131-142
52. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol. 2003;81:355-363
53. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693
54. Ozerdem U, Monosov E, Stallcup WB. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res. 2002;63:129-134
55. Fukushi J, Makagiansar IT, Stallcup WB. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell. 2004;15:3580-3590
56. Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylationdependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156:744-758
57. Croci DO, Salatino M, Rubinstein N, et al. Disrupting galectin1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma. J Exp Med. 2012;209:1985-2000
58. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006;103:15975-15980
59. Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology. 2014;24:886-891
60. Lim MJ, Ahn J, Yi JY, et al. Induction of galectin-1 by TGFbeta1 accelerates fibrosis through enhancing nuclear retention of Smad2. Exp Cell Res. 2014;326:125-135
61. Okano K, Tsuruta Y, Yamashita T, Takano M, Echida Y, Nitta K. Suppression of renal fibrosis by galectin-1 in high glucosetreated renal epithelial celss. Exp Cell Res. 2010;316:3282-3291